Apixaban Dosing and Bleeding Risk in Older Adult With Recent GI Bleed
An 81-year-old woman with atrial fibrillation (CHA2DS2-VASc 5), hypertension, and type 2 diabetes presents for follow-up. Eight months ago she had a lower GI bleed requiring transfusion; colonoscopy showed diverticular bleeding. Current medications: apixaban 5 mg twice daily, metoprolol succinate 50 mg daily, lisinopril 10 mg daily, metformin 500 mg twice daily, aspirin 81 mg daily (started after a transient ischemic attack 3 years ago). Weight 54 kg, serum creatinine 1.5 mg/dL (CrCl approximately 28 mL/min by Cockcroft-Gault), hemoglobin 10.8 g/dL, platelets 180,000/µL. She reports two episodes of dark stools in the past week but no dizziness. She asks whether her blood thinner is 'too strong' and whether the aspirin is still needed.
1. Is the apixaban dose appropriate for this patient? Justify your answer using her specific clinical data.
Read the worked answer
The dose is too high. Apixaban labeling reduces the dose to 2.5 mg twice daily when at least two of the following are present: age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL.
She meets all three:
- Age 81 years
- Weight 54 kg
- Serum creatinine 1.5 mg/dL
Therefore the appropriate dose is apixaban 2.5 mg twice daily, not 5 mg twice daily. The reduced dose is not based on CrCl alone; her CrCl of 28 mL/min does not independently require a further reduction below 2.5 mg twice daily. Continuing 5 mg twice daily in a patient who meets all three reduction criteria substantially increases bleeding risk, especially with a recent GI bleed and low hemoglobin. Recommend dose reduction, review renal function and CBC, and document the rationale.
2. Should aspirin be continued? Explain the competing risks and your recommendation.
Read the worked answer
Aspirin should generally be discontinued in this patient.
Reasoning:
- Her prior TIA was in the setting of atrial fibrillation; anticoagulation with apixaban is the appropriate therapy for stroke prevention.
- Adding aspirin to an anticoagulant increases major and GI bleeding risk without a clear net benefit for secondary prevention in AF unless there is a separate indication such as recent acute coronary syndrome or coronary stent.
- She has a recent diverticular bleed, hemoglobin 10.8 g/dL, and new dark stools, which raises concern for recurrent GI bleeding.
Recommend stopping aspirin, confirming there is no recent ACS/stent indication, adding a proton pump inhibitor, checking hemoglobin and stool characteristics, and counseling on NSAID avoidance and alcohol limitation. If a brief interruption of apixaban is needed for active bleeding, coordinate with gastroenterology rather than stopping anticoagulation permanently.
3. How would you manage the two episodes of dark stools, assuming she is hemodynamically stable?
Read the worked answer
Treat this as possible recurrent GI bleeding until proven otherwise:
- Check orthostatic vital signs, repeat CBC, renal function, and stool studies; estimate blood loss and transfusion need.
- Review all medications for additional bleeding risk (NSAIDs, antiplatelets, SSRIs) and discontinue unnecessary agents.
- If bleeding is minor and she remains stable, apixaban can often be continued with close monitoring; if there is evidence of significant bleeding, hold apixaban and consult gastroenterology for evaluation.
- Reversal agents are reserved for major bleeding or urgent procedures; do not reverse prophylactically for dark stools alone.
- After hemostasis is confirmed, restart anticoagulation as soon as safe because stroke risk is high; involve the patient in shared decision-making about bleeding versus stroke risk.
- Document a monitoring plan including hemoglobin checks and return precautions.